Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Short-term Investments (2023 - 2025)

Collegium Pharmaceutical has reported Short-term Investments over the past 3 years, most recently at $19.8 million for Q4 2025.

  • Quarterly results put Short-term Investments at $19.8 million for Q4 2025, down 20.6% from a year ago — trailing twelve months through Dec 2025 was $19.8 million (down 20.6% YoY), and the annual figure for FY2025 was $19.8 million, down 20.6%.
  • Short-term Investments for Q4 2025 was $19.8 million at Collegium Pharmaceutical, down from $135.8 million in the prior quarter.
  • Over the last five years, Short-term Investments for COLL hit a ceiling of $135.8 million in Q3 2025 and a floor of $19.8 million in Q4 2025.
  • Median Short-term Investments over the past 3 years was $81.0 million (2024), compared with a mean of $74.1 million.
  • Peak annual rise in Short-term Investments hit 136.66% in 2024, while the deepest fall reached 65.08% in 2024.
  • Collegium Pharmaceutical's Short-term Investments stood at $71.6 million in 2023, then plummeted by 65.08% to $25.0 million in 2024, then dropped by 20.6% to $19.8 million in 2025.
  • The last three reported values for Short-term Investments were $19.8 million (Q4 2025), $135.8 million (Q3 2025), and $104.8 million (Q2 2025) per Business Quant data.